<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The AT.LANTUS trial recently demonstrated the efficacy and safety of insulin glargine initiation and maintenance using two different treatment algorithms in poorly controlled type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>This sub-analysis investigated glycemic control and safety in 686 patients switching from premixed insulin (premix) with or without (+/-OADs) to once-daily glargine (+/-OADs/prandial insulin) </plain></SENT>
<SENT sid="2" pm="."><plain>A 24-week, multinational (n=59), multicenter (n=611), randomized study comparing two algorithms (Algorithm 1: clinic-driven titration; Algorithm 2: patient-driven titration) in four glargine+/-OADs treatment groups: alone, once- (OD), twice- (BD) or &gt;twice- (&gt;BD) daily prandial insulin </plain></SENT>
<SENT sid="3" pm="."><plain>After switching to the glargine regimen, HbA(1c) levels significantly improved in the overall group (9.0+/-1.3 to 8.0+/-1.2%; p&lt;0.001) and in <z:hpo ids='HP_0000001'>all</z:hpo> subgroups; fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels also improved in <z:hpo ids='HP_0000001'>all</z:hpo> subgroups (overall: 167.1+/-50.0 to 106.9+/-27.2 mg/dL [9.3+/-2.8 to 5.9+/-1.5 mmol/L]; p&lt;0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> was also low in <z:hpo ids='HP_0000001'>all</z:hpo> four subgroups (&lt; or =1.7%) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with T2DM switching from premix+/-OADs to glargine+/-OADs had significant reductions in glycemic control with a low incidence of severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The addition of prandial (OD, BD or &gt;BD) insulin was associated with further improvements in glycemic control </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide support for the stepwise introduction of prandial insulin to a more physiologic basal-bolus regimen, which is under investigation </plain></SENT>
</text></document>